BridgeBio Pharma's drug successes boost valuation to $100+, with strong pipeline and rising sales forecasts.

BridgeBio Pharma has achieved multiple clinical and commercial successes, including outperforming trials for its drug Infigratinib and strong sales from Attruby, which now has increased peak sales guidance. Recent competitor setbacks and new data showing additional benefits of Attruby further improve the company's commercial outlook. The analyst maintains a valuation of at least $100 per share currently, with a long-term target above $300, reflecting confidence in BridgeBio's pipeline execution and growing revenue projections.